The Protein Mistake Destroying Your Muscle- AMA Live

Nephrologist Dr. Sean Hashmi breaks down 9 new studies from the last 60 days on kidney disease, metabolic health, and longevity, including the first FDA-approved GLP-1 for fatty liver, the gut-kidney axis behind calcium oxalate kidney stones, and what the children of centenarians actually eat. This is the monthly research recap from a board-certified nephrologist and obesity medicine specialist. Kidney disease, GLP-1s, fatty liver, sarcopenia, sleep apnea, and biological aging, in one session. Watch to learn which findings are worth bringing to your next doctor's appointment, the specific lab values that change the conversation, and one action you can start tonight from each topic. ━━━━━━━━━━━━━━ TIMESTAMPS: 00:00 What changed my mind this year 01:50 Study 1: GLP-1s cut serious infections 21% in CKD 08:55 Study 2: The gut-kidney axis and calcium oxalate stones 13:00 Study 3: Physical function as a kidney warning sign 18:00 Study 4: First GLP-1 approved for fatty liver (Essence) 25:00 Study 5: High-protein diets and muscle loss (the surprise) 30:00 Study 6: CPAP plus GLP-1 and pulmonary hypertension 37:00 Study 7: What centenarian children actually eat 42:00 Study 8: Nicoyans are biologically 2 years younger 46:00 Study 9: The two free interventions that reverse cellular age 52:00 The single takeaway from tonight 56:00 Your questions answered ━━━━━━━━━━━━━━ IN THIS VIDEO: VIGOVI (semaglutide 2.4 mg) is now FDA-approved for non-cirrhotic MASH with F2-F3 fibrosis, the first GLP-1 ever approved for a liver indication. A Korean cohort of 31,968 adults found the highest-protein dietary pattern had 45% higher risk of muscle weakness, the opposite of what most fitness content teaches. The descendants of America's longest-living people are not biohacking. They eat slightly more fish and legumes, slightly less salt and added sugar. That is the entire list. ━━━━━━━━━━━━━━ RESEARCH CITED: Perkovic V, et al. (2024), NEJM. FLOW trial: semaglutide and kidney outcomes in type 2 diabetes and CKD. Sanyal AJ, et al. (2025), NEJM. ESSENCE trial: semaglutide for non-cirrhotic MASH with fibrosis (Part 1 readout). Newman AB, et al. (2025), American Journal of Kidney Diseases. Physical function decline and clinical outcomes in the CRIC study. Wang J, et al. (2024), Nutrients. Dietary macronutrient patterns and incident muscle weakness in the KoGES cohort. Sebastiani P, et al. (2024), Journal of Nutrition in Gerontology and Geriatrics. Diet quality in offspring of centenarians. ━━━━━━━━━━━━━━ SUPPORT THIS CHANNEL Your support keeps these videos free for everyone.    / @seanhashmimd   Tap JOIN next to Subscribe. Thank you. ━━━━━━━━━━━━━━ SUBSCRIBE for weekly evidence-based health videos:    / @seanhashmimd   ━━━━━━━━━━━━━━ CONNECT: Instagram:   / seanhashmimd   Newsletter: https://www.selfprinciple.org/newsletter Website: https://www.selfprinciple.org ━━━━━━━━━━━━━━ MEDICAL DISCLAIMER: This video is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult your healthcare provider before making changes to your health routine. Viewing this content does not establish a doctor-patient relationship. The views and opinions expressed are Dr. Hashmi's personal professional opinions and do not represent the views of any employer, healthcare institution, or affiliated organization. #KidneyDisease #GLP1 #FattyLiver #KidneyHealth #EvidenceBasedMedicine #SeanHashmiMD